Drug Companies Focus on Improving Long-term Outcome of New Drugs
Technological advancements in the past few decades have introduced new and innovative treatments for a range of health problems. The advent of organ transplants is one of the most revolutionary developments in the medical space, and attained a considerable amount of acceptance and popularity worldwide. However, while organ transplant has its own share of benefits, it also has the potential to negatively impact the immune system of the recipient due to which, organ transplant rejection medications have come under the spotlight. Immunologists and other stakeholders in the current value chain of the organ transplant rejection medications market are continually investing resources to assess the adaptive responses to solid organ transplantation.
As these studies continue to grow in number, they have played an imperative role in the development of new immunosuppressive drugs– a factor that is likely to aid the growth of the organ transplant rejection medications market during the forecast period (2020-2027). The demand for organ transplant rejection medications is witnessing considerable growth, as these drugs have enhanced short-term graft survival and minimized the rate of acute organ transplant rejection. Despite offering favorable short-term results, stakeholders in the current market landscape are expected to concentrate on improving the long-term outcome of these drugs. The global organ transplant rejection medications market is expected to reach a value of ~US$ 6.3 Bn by the end of the forecast period.
To know the scope of our report Get a Sample on Organ Transplant Rejection Medications Market
Calcineurin Inhibitors to Remain Most Popular Drug Class
The organ transplant rejection medications market is predominantly dominated by kidney transplants, as the number of kidney transplants continues to outnumber other types of organ transplants such as bone marrow transplant, heart transplant, liver transplant, lung transplant, etc. Over the past few years, studies and research activities have focused on assessing the impact of the various organ transplant rejection medications employed post kidney transplantation, including calcineurin inhibitors, mTOR inhibitors, steroids, and antibodies.
In the current scenario, calcineurin inhibitors, including cyclosporine and tacrolimus, are some of the most used organ transplantation rejection medications. In addition, as calcineurin inhibitors hinder the secretion of cytokines and presentation of antigens within the innate immune cells, they curb the T cell priming capacity. These factors play a critical role in the pathogenesis of acute rejection. Stakeholders and drug companies are expected to find new immunosuppressive drugs that will eliminate the long-term negative effects put forward by traditional organ transplant rejection drugs.
Get a glimpse of the in-depth analysis through our Report Brochure
Development of New Immunosuppressive Drugs to Influence Market Growth
Since the inception of solid organ transplantation, the organ transplant rejection medications market has witnessed innovations and developments. The development of new drugs has reduced graft rejection and improved survival by a considerable margin. The development of new organ transplant rejection medications started to gain considerable amount of traction in the 1990s, and these drugs have laid a solid foundation for the development of new drugs in the current era. Drug manufacturers in the organ transplant rejection medications market are primarily focusing on finding solutions to enhance long-term graft survival and minimize the burden of side-effects. In 2011, belatacept exhibited strong potential for biological non-nephrotoxic maintenance immunosuppression. Moreover, belatacept also offered tremendous promise in long-term graft survival. However, due to the fear of rejection, insufficient availability, high costs, and a dearth of supporting data, the adoption of belatacept took a beating due to which, the demand for the existing tacrolimus continued to grow at a significant pace.
Due to various factors, the development of new organ transplant rejection medications hit a roadblock post the approval of belatacept. However, in the current scenario, clinical trials of other compounds, including CFZ533 is in progress, which could provide a much-needed breakthrough for kidney transplantation. In addition, apart from the classical development of new organ transplant rejection medications, several companies in the organ transplant rejection medications market are likely to invest a significant amount of resources on the development of new cell therapies, which could possibly replace conventional organ transplant rejection medications in the years to come.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
The global organ transplant rejection medications market is expected to grow at a CAGR of ~3% during the forecast period. The market growth can be primarily attributed to research and development activities that are expected to enhance the immune responses to solid organ transplantation. In addition, stakeholders in the current market landscape should focus on improving long-term graft survival and minimize the rate of acute rejection. As kidney transplants are set to remain the most common organ transplantation procedure, research activities will primarily focus on the production of new drugs that improve the success of kidney transplantation. Attaining FDA approval should remain priority for the companies in the organ transplant rejection medications market during the assessment period.
Organ Transplant Rejection Medications Market: Overview
- According to Transparency Market Research’s latest market report on the organ transplant rejection medications market for the historical period of 2017–2018 and forecast period of 2019–2027, high prevalence and increase in incidence of several acute and chronic disorders worldwide are anticipated to drive the global organ transplant rejection medications market
- According to the report, the global organ transplant rejection medications market was valued at ~US$ 4.7 Bn in 2018. The organ transplant rejection medications market is projected to expand at a CAGR of ~3% from 2019 to 2027.
High Patient Population and Rise in Geriatric Population to Propel Market: A Key Driver
- Increase in incidence of chronic diseases of liver, heart, kidneys, and pancreas and blood disorders such as leukemia and aplastic anemia have augmented the demand for organ transplants or replacements
- Rise in geriatric population directly affects the demand for organ transplants, primarily due to the higher susceptibility to kidney and heart diseases among this population
- Therefore, rise in incidence of chronic diseases and increase in geriatric population across the globe are fueling the organ transplant rejection medications market
Rise in Healthcare Spending & Improvement in Healthcare Infrastructure
- Increase in patient awareness about personal health boosts the demand for medical devices. Patients are more aware and proactive about their health and are willing to seek a physician's advice at an early stage.
- Increase in per capita disposable income is encouraging people to spend more on healthcare facilities, which, in turn, propels the global organ transplant rejection medications market. Advertisements have increased public visibility of new technology, thereby generating interest among chronic patients.
- Changing demographics in emerging economies such as China, India, Brazil, and South Africa are expected to provide significant opportunities for organ transplants
- Public and private healthcare expenditure is expected to increase in these countries, which is likely to drive the organ transplant rejection medications market
- Increase in healthcare expenditure, rise in global per capita income, and improvement in healthcare infrastructure and government reimbursement programs in developed as well as developing countries are likely to propel the organ transplant rejection medications market in the near future
Lack of Donor Organs to Hamper Organ Transplant Rejection Medications Market
- The gap between demand and supply continues to widen despite advancements in medicine and technology, and increase in awareness about organ donation and transplantation
- Other factors that hamper the market comprise low physician wages, informal payments, and negative public attitude toward organ donation and transplantation
- Organ transplantation procedures, especially for kidney and heart are well-established treatment methods after the introduction of immunosuppressive drugs that overcome the issues associated with transplant rejection. However, there is considerable shortage of eligible donor organs, and patients across the globe are on waiting lists for organ transplantation.
- According to the Organ Procurement and Transplantation Network data report, around 122,560 people in the U.S. are listed in the organ transplantation waiting list. The total transplants performed in the first six months of 2015 stood at 15,083 as against 7,322 donors. The average waiting time for transplant for patients with liver failure is 26 months and about three years for lung transplant. Furthermore, 22 people succumb to death every day while waiting for organ transplant.
Organ Transplant Rejection Medications Market: Competition Landscape
- This report profiles major players in the global organ transplant rejection medications market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
- The organ transplant rejection medications market is moderately fragmented with the presence of a few large-scale players present in international markets and few small-scale players in regional markets. The top four to five players hold majority share of the global organ transplant rejection medications market.
- Prominent players operating in the global organ transplant rejection medications market include
- GlaxoSmithKline plc,
- Novartis AG,
- F. Hoffmann-La Roche Ltd.,
- Astellas Pharma, Inc.,
- Pfizer, Inc.,
- AbbVie, Inc.,
- Allergan plc.,
- Bristol-Myers Squibb Company (BMS), and
- Sanofi
Organ Transplant Rejection Medications Market: Key Developments
- In March 2019, Astellas Pharma US, Inc. launched PROGRAF Granules (tacrolimus for oral suspension) in the U.S. This drug is a combination with other immunosuppressants to help prevent organ rejection in people who have had a liver, heart, or kidney transplant
- In July 2019, Mylan and Pfizer's generic drugs business units merged to create a global pharmaceutical company that is uniquely positioned to meet the changing medical needs of the world. Consolidation would lead to greater global scale and regional coverage, including leadership in global and other emerging markets.
- The report on the global organ transplant rejection medications market discusses individual strategies, followed by company profiles of organ transplant rejection medication providers. The ‘Competition Landscape’ section has been included in the global organ transplant rejection medications market report to provide readers with a dashboard view of key market players operating in the global organ transplant rejection medications market.
Organ Transplant Rejection Medications Market – Scope of the Report
TMR’s report on the global organ transplant rejection medications market studies past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the market during the forecast period from 2019 to 2027. The report provides the overall market revenue of the global organ transplant rejection medications market for the period of 2017–2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global organ transplant rejection medications market during the forecast period.
The report has been prepared after an extensive primary and secondary research. Primary research involves bulk of research efforts wherein, analysts carry out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global organ transplant rejection medications market.
Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global organ transplant rejection medications market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the global organ transplant rejection medications market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global organ transplant rejection medications market.
The report delves into the competition landscape of the global organ transplant rejection medications market. Key players operating in the global organ transplant rejection medications market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the global organ transplant rejection medications market that have been profiled in this report.
Key Questions Answered in Organ Transplant Rejection Medications Market Report
- What is the scope of growth of companies in the organ transplant rejection medications market?
- What will be the Y-o-Y growth of the organ transplant rejection medications market between 2019 and 2027?
- What is the influence of changing trends in technologies on the global organ transplant rejection medications market?
- Will North America continue to remain the most profitable regional market for organ transplant rejection medication providers?
- Which factors will impede the growth of the global organ transplant rejection medications market during the forecast period?
- Which are the leading companies in the global organ transplant rejection medications market?
Research Methodology
A unique research methodology has been utilized by TMR to conduct a comprehensive research on the growth of the global organ transplant rejection medications market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary sources referred to by analysts during the production of the global organ transplant rejection medications market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who have contributed to the production of TMR’s study on the organ transplant rejection medications market as primary sources.
These primary and secondary sources have provided exclusive information during interviews, which serves as a validation from organ transplant rejection medications market leaders. Access to extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global organ transplant rejection medications market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global organ transplant rejection medications market more reliably and accurately.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Europe
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Organ Transplant Rejection Medications Market – Segmentation
|
Drug Class |
|
|
|
|
|
Distribution Channel |
|
|
|
|
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Organ Transplant Rejection Medications Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Organ Transplant Rejection Medications Market Analysis and Forecast, 2017–2027
5. Market Outlook
5.1. Pipeline Analysis
5.2. Key Mergers & Acquisitions
6. Global Organ Transplant Rejection Medications Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2027
6.3.1. Calcineurin Inhibitors
6.3.2. Antiproliferative Agents
6.3.3. mTOR Inhibitors
6.3.4. Antibodies
6.3.5. Steroids
6.4. Market Attractiveness, by Drug Class
7. Global Organ Transplant Rejection Medications Market Analysis and Forecast, by Transplant Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Transplant Type, 2017–2027
7.3.1. Kidney Transplant
7.3.2. Bone Marrow Transplant
7.3.3. Liver Transplant
7.3.4. Heart Transplant
7.3.5. Lung Transplant
7.3.6. Other Transplants
7.4. Market Attractiveness, by Transplant Type
8. Global Organ Transplant Rejection Medications Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2027
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel
9. Global Organ Transplant Rejection Medications Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Organ Transplant Rejection Medications Market Analysis and Forecast
10.1. Introduction
10.2. Market Value Forecast, by Drug Class, 2017–2027
10.2.1. Calcineurin Inhibitors
10.2.2. Antiproliferative Agents
10.2.3. mTOR Inhibitors
10.2.4. Antibodies
10.2.5. Steroids
10.3. Market Value Forecast, by Transplant Type, 2017–2027
10.3.1. Kidney Transplant
10.3.2. Bone Marrow Transplant
10.3.3. Liver Transplant
10.3.4. Heart Transplant
10.3.5. Lung Transplant
10.3.6. Other Transplants
10.4. Market Value Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Transplant Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Organ Transplant Rejection Medications Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast, by Drug Class, 2017–2027
11.2.1. Calcineurin Inhibitors
11.2.2. Antiproliferative Agents
11.2.3. mTOR Inhibitors
11.2.4. Antibodies
11.2.5. Steroids
11.3. Market Value Forecast, by Transplant Type, 2017–2027
11.3.1. Kidney Transplant
11.3.2. Bone Marrow Transplant
11.3.3. Liver Transplant
11.3.4. Heart Transplant
11.3.5. Lung Transplant
11.3.6. Other Transplants
11.4. Market Value Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Transplant Type
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Organ Transplant Rejection Medications Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast, by Drug Class, 2017–2027
12.2.1. Calcineurin Inhibitors
12.2.2. Antiproliferative Agents
12.2.3. mTOR Inhibitors
12.2.4. Antibodies
12.2.5. Steroids
12.3. Market Value Forecast, by Transplant Type, 2017–2027
12.3.1. Kidney Transplant
12.3.2. Bone Marrow Transplant
12.3.3. Liver Transplant
12.3.4. Heart Transplant
12.3.5. Lung Transplant
12.3.6. Other Transplants
12.4. Market Value Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Transplant Type
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Organ Transplant Rejection Medications Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast, by Drug Class, 2017–2027
13.2.1. Calcineurin Inhibitors
13.2.2. Antiproliferative Agents
13.2.3. mTOR Inhibitors
13.2.4. Antibodies
13.2.5. Steroids
13.3. Market Value Forecast, by Transplant Type, 2017–2027
13.3.1. Kidney Transplant
13.3.2. Bone Marrow Transplant
13.3.3. Liver Transplant
13.3.4. Heart Transplant
13.3.5. Lung Transplant
13.3.6. Other Transplants
13.4. Market Value Forecast, by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Transplant Type
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Organ Transplant Rejection Medications Market Analysis and Forecast
14.1. Introduction
14.2. Market Value Forecast, by Drug Class, 2017–2027
14.2.1. Calcineurin Inhibitors
14.2.2. Antiproliferative Agents
14.2.3. mTOR Inhibitors
14.2.4. Antibodies
14.2.5. Steroids
14.3. Market Value Forecast, by Transplant Type, 2017–2027
14.3.1. Kidney Transplant
14.3.2. Bone Marrow Transplant
14.3.3. Liver Transplant
14.3.4. Heart Transplant
14.3.5. Lung Transplant
14.3.6. Other Transplants
14.4. Market Value Forecast, by Distribution Channel, 2017–2027
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Transplant Type
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Top Players Operating in the Market
15.2. Company Profiles
15.2.1. GlaxoSmithKline plc
15.2.1.1. Company Overview
15.2.1.2. Company Financials
15.2.1.3. Growth Strategies
15.2.1.4. SWOT Analysis
15.2.2. Novartis AG
15.2.2.1. Company Overview
15.2.2.2. Company Financials
15.2.2.3. Growth Strategies
15.2.2.4. SWOT Analysis
15.2.3. F. Hoffmann-La Roche Ltd.
15.2.3.1. Company Overview
15.2.3.2. Company Financials
15.2.3.3. Growth Strategies
15.2.3.4. SWOT Analysis
15.2.4. Astellas Pharma, Inc.
15.2.4.1. Company Overview
15.2.4.2. Company Financials
15.2.4.3. Growth Strategies
15.2.4.4. SWOT Analysis
15.2.5. Pfizer, Inc.
15.2.5.1. Company Overview
15.2.5.2. Company Financials
15.2.5.3. Growth Strategies
15.2.5.4. SWOT Analysis
15.2.6. AbbVie, Inc.
15.2.6.1. Company Overview
15.2.6.2. Company Financials
15.2.6.3. Growth Strategies
15.2.6.4. SWOT Analysis
15.2.7. Allergan plc.
15.2.7.1. Company Overview
15.2.7.2. Company Financials
15.2.7.3. Growth Strategies
15.2.7.4. SWOT Analysis
15.2.8. Bristol-Myers Squibb Company (BMS)
15.2.8.1. Company Overview
15.2.8.2. Company Financials
15.2.8.3. Growth Strategies
15.2.8.4. SWOT Analysis
15.2.9. Sanofi
15.2.9.1. Company Overview
15.2.9.2. Company Financials
15.2.9.3. Growth Strategies
15.2.9.4. SWOT Analysis
List of Tables
Table 01: Pipeline Analysis: Organ Transplant Rejection Medications Market
Table 02: Key Merger and Acquisitions
Table 03: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 04: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017–2027
Table 05: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 06: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 07: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 08: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017–2027
Table 09: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 10: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 11: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 12: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017–2027
Table 13: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 14: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 15: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 16: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017–2027
Table 17: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 18: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 19: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 20: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017–2027
Table 21: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 22: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 23: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 24: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017–2027
Table 25: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 26: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
List of Figures
Figure 01: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027
Figure 02: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Transplant Type, 2018
Figure 03: Global Organ Transplant Rejection Medications Market, by Drug Class, 2018
Figure 04: Global Organ Transplant Rejection Medications Market, by Distribution Channel, 2018
Figure 05: Global Organ Transplant Rejection Medications Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 06: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 07: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Y-o-Y Growth, by Calcineurin Inhibitors, 2017–2027
Figure 08: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Y-o-Y Growth, by Antiproliferative Agents, 2017–2027
Figure 09: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Y-o-Y Growth, by mTOR Inhibitors, 2017–2027
Figure 10: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Y-o-Y Growth, by Antibodies, 2017–2027
Figure 11: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Y-o-Y Growth, by Steroids, 2017–2027
Figure 12: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2017–2027
Figure 13: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2018 and 2027
Figure 14: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Y-o-Y Growth, by Kidney Transplant, 2017–2027
Figure 15: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Y-o-Y Growth, by Bone Marrow Transplant, 2017–2027
Figure 16: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Y-o-Y Growth, by Liver Transplant, 2017–2027
Figure 17: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Y-o-Y Growth, by Heart Transplant, 2017–2027
Figure 18: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Y-o-Y Growth, by Lung Transplant, 2017–2027
Figure 19: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Y-o-Y Growth, by Other Transplants, 2017–2027
Figure 20: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2017–2027
Figure 21: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 22: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027
Figure 23: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027
Figure 24: Global Organ Transplant Rejection Medications Market Value (US$ Mn) and Y-o-Y Growth, by Online Pharmacies, 2017–2027
Figure 25: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2017–2027
Figure 26: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Region, 2018 and 2027
Figure 27: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Region, 2019–2027
Figure 28: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 29: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 30: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 31: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2018 and 2027
Figure 32: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2019–2027
Figure 33: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 34: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 35: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Country, 2018 and 2027
Figure 36: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country, 2019–2027
Figure 37: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 38: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 39: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 40: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2018 and 2027
Figure 41: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2019–2027
Figure 42: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 43: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 44: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 45: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 46: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 47: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 48: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 49: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2018 and 2027
Figure 50: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2019–2027
Figure 51: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 52: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 53: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 54: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 55: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 56: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 57: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 58: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2018 and 2027
Figure 59: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2019–2027
Figure 60: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 61: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 62: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 63: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 64: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 65: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 66: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 67: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2018 and 2027
Figure 68: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2019–2027
Figure 69: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 70: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 71: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 72: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 73: Top Players Operating in the Market
